Skip to content

Study · Randomized controlled trial · 2021

1 result

Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.

Sharma A, Greene S, Vaduganathan M, Fudim M, Ambrosy AP, Sun JL, McNulty SE, Hernandez AF, Borlaug BA, Velazquez EJ, Mentz RJ, DeVore AD, Alhanti B, Margulies K, Felker GM

ESC heart failure1 Jun 2021Cited by 13 (Europe PMC)

PMID34061470 (opens in a new tab)PMCIDPMC8318489 (opens in a new tab)DOI10.1002/ehf2.13348 (opens in a new tab)PepBankPUB-34061470
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with heart failure with reduced ejection fraction and a recent hospitalization, GDF-15 levels stayed stable in participants randomized to liraglutide.

    In plain wordsIn adults with heart failure and a recent hospital stay, blood levels of GDF-15 stayed stable with liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeGDF-15 level change over 30 days
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GDF-15 levels remained stable among participants randomized to liraglutide.
    1 context sentence
    Summary · context
    FIGHT was a randomized clinical trial testing the effect of liraglutide (vs. placebo) among 300 participants with HFrEF and a recent HHF.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.